{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:18:09Z","timestamp":1794856689010,"version":"4.9.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The most prominent homozygous deletions in cancer affect chromosome 9p21.3 and eliminate <jats:italic>CDKN2A\/B<\/jats:italic> tumor suppressors, disabling a cell-intrinsic barrier to tumorigenesis. Half of 9p21.3 deletions, however, also encompass a type I interferon (IFN) gene cluster; the consequences of this co-deletion remain unexplored. To functionally dissect 9p21.3 and other large genomic deletions, we developed a flexible deletion engineering strategy, MACHETE (molecular alteration of chromosomes with engineered tandem elements). Applying MACHETE to a syngeneic mouse model of pancreatic cancer, we found that co-deletion of the IFN cluster promoted immune evasion, metastasis and immunotherapy resistance. Mechanistically, IFN co-deletion disrupted type I IFN signaling in the tumor microenvironment, leading to marked changes in infiltrating immune cells and escape from CD8<jats:sup>+<\/jats:sup>\u2009T-cell surveillance, effects largely driven by the poorly understood interferon epsilon. These results reveal a chromosomal deletion that disables both cell-intrinsic and cell-extrinsic tumor suppression and provide a framework for interrogating large deletions in cancer and beyond.<\/jats:p>","DOI":"10.1038\/s43018-022-00443-5","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T17:03:57Z","timestamp":1667840637000},"page":"1367-1385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-7707","authenticated-orcid":false,"given":"Francisco M.","family":"Barriga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaloyan M.","family":"Tsanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jui","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timour","family":"Baslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra N.","family":"Wuest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Del Priore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigita","family":"Me\u0161kauskait\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geulah","family":"Livshits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Direna","family":"Alonso-Curbelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Chaves-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Bar-Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-3023","authenticated-orcid":false,"given":"Christine A.","family":"Iacobuzio-Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiyaz","family":"Notta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-3291","authenticated-orcid":false,"given":"Ronan","family":"Chaligne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-8817","authenticated-orcid":false,"given":"Dana","family":"Pe\u2019er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-9650","authenticated-orcid":false,"given":"Scott W.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"443_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","volume":"458","author":"MR Stratton","year":"2009","unstructured":"Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719\u2013724 (2009).","journal-title":"Nature"},{"key":"443_CR2","doi-asserted-by":"publisher","unstructured":"Vasudevan, A. et al. Aneuploidy as a promoter and suppressor of malignant growth. Nat. Rev. Cancer https:\/\/doi.org\/10.1038\/s41568-020-00321-1 (2021).","DOI":"10.1038\/s41568-020-00321-1"},{"key":"443_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"443_CR4","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/ng.2760","volume":"45","author":"TI Zack","year":"2013","unstructured":"Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134\u20131140 (2013).","journal-title":"Nat. Genet."},{"key":"443_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1383-5742(00)00006-5","volume":"462","author":"F Mitelman","year":"2000","unstructured":"Mitelman, F. Recurrent chromosome aberrations in cancer. Mutation Res. 462, 247\u2013253 (2000).","journal-title":"Mutation Res."},{"key":"443_CR6","doi-asserted-by":"publisher","unstructured":"Smith, J. C. & Sheltzer, J. M. Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. eLife https:\/\/doi.org\/10.7554\/eLife.39217 (2018).","DOI":"10.7554\/eLife.39217"},{"key":"443_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","volume":"578","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112\u2013121 (2020).","journal-title":"Nature"},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.cell.2020.01.032","volume":"180","author":"S Kumar","year":"2020","unstructured":"Kumar, S. et al. Passenger mutations in more than 2,500 cancer genomes: overall molecular functional impact and consequences. Cell 180, 915\u2013927 (2020).","journal-title":"Cell"},{"key":"443_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.trecan.2015.10.002","volume":"1","author":"FL Muller","year":"2015","unstructured":"Muller, F. L., Aquilanti, E. A. & DePinho, R. A. Collateral lethality: a new therapeutic strategy in oncology. Trends Cancer 1, 161\u2013173 (2015).","journal-title":"Trends Cancer"},{"key":"443_CR10","doi-asserted-by":"publisher","first-page":"8212","DOI":"10.1073\/pnas.1206062109","volume":"109","author":"W Xue","year":"2012","unstructured":"Xue, W. et al. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc. Natl Acad. Sci. USA 109, 8212\u20138217 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"443_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccell.2016.04.003","volume":"29","author":"Y Cai","year":"2016","unstructured":"Cai, Y. et al. Loss of chromosome 8p governs tumor progression and drug response by altering lipid metabolism. Cancer Cell 29, 751\u2013766 (2016).","journal-title":"Cancer Cell"},{"key":"443_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature17157","volume":"531","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature 531, 471\u2013475 (2016).","journal-title":"Nature"},{"key":"443_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.cell.2013.10.011","volume":"155","author":"T Davoli","year":"2013","unstructured":"Davoli, T. et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155, 948\u2013962 (2013).","journal-title":"Cell"},{"key":"443_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676\u2013689 (2018).","journal-title":"Cancer Cell"},{"key":"443_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/carcin\/bgz108","volume":"41","author":"A Mishra","year":"2020","unstructured":"Mishra, A. et al. Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing. Carcinogenesis 41, 334\u2013344 (2020).","journal-title":"Carcinogenesis"},{"key":"443_CR16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/bit.25490","volume":"112","author":"Z He","year":"2015","unstructured":"He, Z. et al. Highly efficient targeted chromosome deletions using CRISPR\/Cas9. Biotechnol. Bioeng. 112, 1060\u20131064 (2015).","journal-title":"Biotechnol. Bioeng."},{"key":"443_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/35096061","volume":"2","author":"CJ Sherr","year":"2001","unstructured":"Sherr, C. J. The INK4a\/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2, 731\u2013737 (2001).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","volume":"88","author":"M Serrano","year":"1997","unstructured":"Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593\u2013602 (1997).","journal-title":"Cell"},{"key":"443_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0092-8674(00)80452-3","volume":"91","author":"T Kamijo","year":"1997","unstructured":"Kamijo, T. et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649\u2013659 (1997).","journal-title":"Cell"},{"key":"443_CR20","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1078-0432.CCR-16-2128","volume":"23","author":"D Balli","year":"2017","unstructured":"Balli, D., Rech, A. J., Stanger, B. Z. & Vonderheide, R. H. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clin. Cancer Res. 23, 3129\u20133138 (2017).","journal-title":"Clin. Cancer Res."},{"key":"443_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","volume":"49","author":"J Li","year":"2018","unstructured":"Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49, 178\u2013193 (2018).","journal-title":"Immunity"},{"key":"443_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397\u2013404 (2016).","journal-title":"Cell"},{"key":"443_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909\u2013918 (2020).","journal-title":"Nat. Med."},{"key":"443_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1474-9726.2012.00871.x","volume":"11","author":"WR Jeck","year":"2012","unstructured":"Jeck, W. R., Siebold, A. P. & Sharpless, N. E. Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell 11, 727\u2013731 (2012).","journal-title":"Aging Cell"},{"key":"443_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/dvg.22915","volume":"54","author":"K Boroviak","year":"2016","unstructured":"Boroviak, K., Doe, B., Banerjee, R., Yang, F. & Bradley, A. Chromosome engineering in zygotes with CRISPR\/Cas9. Genesis 54, 78\u201385 (2016).","journal-title":"Genesis"},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer 16, 131\u2013144 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"443_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291\u2013304 (2018).","journal-title":"Cell"},{"key":"443_CR28","first-page":"2969","volume":"6","author":"RH Hruban","year":"2000","unstructured":"Hruban, R. H., Goggins, M., Parsons, J. & Kern, S. E. Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969\u20132972 (2000).","journal-title":"Clin. Cancer Res."},{"key":"443_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-018-0481-8","volume":"561","author":"AP Makohon-Moore","year":"2018","unstructured":"Makohon-Moore, A. P. et al. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561, 201\u2013205 (2018).","journal-title":"Nature"},{"key":"443_CR30","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1038\/sj.onc.1206589","volume":"22","author":"S Sasaki","year":"2003","unstructured":"Sasaki, S. et al. Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene 22, 3792\u20133798 (2003).","journal-title":"Oncogene"},{"key":"443_CR31","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/sj.onc.1210832","volume":"27","author":"T Harada","year":"2008","unstructured":"Harada, T. et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 27, 1951\u20131960 (2008).","journal-title":"Oncogene"},{"key":"443_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature25459","volume":"554","author":"S Mueller","year":"2018","unstructured":"Mueller, S. et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 554, 62\u201368 (2018).","journal-title":"Nature"},{"key":"443_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836\u2013847 (2012).","journal-title":"Cancer Cell"},{"key":"443_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ccr.2010.10.020","volume":"18","author":"KE Lee","year":"2010","unstructured":"Lee, K. E. & Bar-Sagi, D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 18, 448\u2013458 (2010).","journal-title":"Cancer Cell"},{"key":"443_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/2159-8290.CD-15-0843","volume":"6","author":"Y Pylayeva-Gupta","year":"2016","unstructured":"Pylayeva-Gupta, Y. et al. IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov. 6, 247\u2013255 (2016).","journal-title":"Cancer Discov."},{"key":"443_CR36","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1073\/pnas.0601273103","volume":"103","author":"N Bardeesy","year":"2006","unstructured":"Bardeesy, N. et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl Acad. Sci. USA 103, 5947\u20135952 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"443_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature10803","volume":"482","author":"M DuPage","year":"2012","unstructured":"DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405\u2013409 (2012).","journal-title":"Nature"},{"key":"443_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.it.2022.03.003","volume":"43","author":"P Spiliopoulou","year":"2022","unstructured":"Spiliopoulou, P. et al. All is not lost: learning from 9p21 loss in cancer. Trends Immunol. 43, 379\u2013390 (2022).","journal-title":"Trends Immunol."},{"key":"443_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2020.03.008","volume":"181","author":"M Ruscetti","year":"2020","unstructured":"Ruscetti, M. et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell 181, 424\u2013441 (2020).","journal-title":"Cell"},{"key":"443_CR40","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20130590","volume":"211","author":"X Fan","year":"2014","unstructured":"Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P. & Allison, J. P. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J. Exp. Med. 211, 715\u2013725 (2014).","journal-title":"J. Exp. Med."},{"key":"443_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"443_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41587-021-01033-z","volume":"40","author":"E Dann","year":"2022","unstructured":"Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D. & Marioni, J. C. Differential abundance testing on single-cell data using k-nearest neighbor graphs. Nat. Biotechnol. 40, 245\u2013253 (2022).","journal-title":"Nat. Biotechnol."},{"key":"443_CR43","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res."},{"key":"443_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231\u2013240 (2020).","journal-title":"Nat. Genet."},{"key":"443_CR45","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224\u20131231 (2012).","journal-title":"Nat. Med."},{"key":"443_CR46","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1158\/0008-5472.CAN-09-0145","volume":"69","author":"Y Kadariya","year":"2009","unstructured":"Kadariya, Y. et al. Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res. 69, 5961\u20135969 (2009).","journal-title":"Cancer Res."},{"key":"443_CR47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/icb.2012.15","volume":"90","author":"PJ Hertzog","year":"2012","unstructured":"Hertzog, P. J. Overview. Type I interferons as primers, activators and inhibitors of innate and adaptive immune responses. Immunol. Cell Biol. 90, 471\u2013473 (2012).","journal-title":"Immunol. Cell Biol."},{"key":"443_CR48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2018.05.013","volume":"34","author":"C Vanpouille-Box","year":"2018","unstructured":"Vanpouille-Box, C., Demaria, S., Formenti, S. C. & Galluzzi, L. Cytosolic DNA sensing in organismal tumor control. Cancer Cell 34, 361\u2013378 (2018).","journal-title":"Cancer Cell"},{"key":"443_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 5606 (2021).","journal-title":"Nat. Commun."},{"key":"443_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","volume":"34","author":"MB Fuertes","year":"2013","unstructured":"Fuertes, M. B., Woo, S. R., Burnett, B., Fu, Y. X. & Gajewski, T. F. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34, 67\u201373 (2013).","journal-title":"Trends Immunol."},{"key":"443_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cyto.2016.01.010","volume":"89","author":"A Ortiz","year":"2017","unstructured":"Ortiz, A. & Fuchs, S. Y. Anti-metastatic functions of type 1 interferons: foundation for the adjuvant therapy of cancer. Cytokine 89, 4\u201311 (2017).","journal-title":"Cytokine"},{"key":"443_CR52","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.molcel.2014.12.030","volume":"57","author":"O Litvin","year":"2015","unstructured":"Litvin, O. et al. Interferon \u03b1\/\u03b2 enhances the cytotoxic response of MEK inhibition in melanoma. Mol. Cell 57, 784\u2013796 (2015).","journal-title":"Mol. Cell"},{"key":"443_CR53","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1126\/science.8009221","volume":"264","author":"U M\u00fcller","year":"1994","unstructured":"M\u00fcller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918\u20131921 (1994).","journal-title":"Science"},{"key":"443_CR54","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1126\/science.1233321","volume":"339","author":"KY Fung","year":"2013","unstructured":"Fung, K. Y. et al. Interferon-\u03b5 protects the female reproductive tract from viral and bacterial infection. Science 339, 1088\u20131092 (2013).","journal-title":"Science"},{"key":"443_CR55","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"443_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"443_CR57","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-17-3008","volume":"24","author":"Z Ye","year":"2018","unstructured":"Ye, Z. et al. Prevalent homozygous deletions of type I interferon and defensin genes in human cancers associate with immunotherapy resistance. Clin. Cancer Res. 24, 3299\u20133308 (2018).","journal-title":"Clin. Cancer Res."},{"key":"443_CR58","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251\u2013264 (2015).","journal-title":"J. Mol. Diagn."},{"key":"443_CR59","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion, M. et al. Somatic HLA class I Loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 11, 282\u2013292 (2021).","journal-title":"Cancer Discov."},{"key":"443_CR60","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1038\/sj.onc.1209046","volume":"24","author":"D Ahuja","year":"2005","unstructured":"Ahuja, D., S\u00e1enz-Robles, M. T. & Pipas, J. M. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24, 7729\u20137745 (2005).","journal-title":"Oncogene"},{"key":"443_CR61","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"443_CR62","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nbt.3804","volume":"35","author":"AR Perez","year":"2017","unstructured":"Perez, A. R. et al. GuideScan software for improved single and paired CRISPR guide RNA design. Nat. Biotechnol. 35, 347\u2013349 (2017).","journal-title":"Nat. Biotechnol."},{"key":"443_CR63","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.celrep.2016.09.092","volume":"17","author":"MC Gundry","year":"2016","unstructured":"Gundry, M. C. et al. Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR\/Cas9. Cell Rep 17, 1453\u20131461 (2016).","journal-title":"Cell Rep"},{"key":"443_CR64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1101\/gad.232082.113","volume":"28","author":"M Saborowski","year":"2014","unstructured":"Saborowski, M. et al. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev. 28, 85\u201397 (2014).","journal-title":"Genes Dev"},{"key":"443_CR65","doi-asserted-by":"publisher","first-page":"e95236","DOI":"10.1371\/journal.pone.0095236","volume":"9","author":"LE Dow","year":"2014","unstructured":"Dow, L. E. et al. Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PLoS ONE 9, e95236 (2014).","journal-title":"PLoS ONE"},{"key":"443_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"443_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"443_CR68","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"443_CR69","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1101\/gr.188060.114","volume":"25","author":"T Baslan","year":"2015","unstructured":"Baslan, T. et al. Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. Genome Res. 25, 714\u2013724 (2015).","journal-title":"Genome Res."},{"key":"443_CR70","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature09807","volume":"472","author":"N Navin","year":"2011","unstructured":"Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90\u201394 (2011).","journal-title":"Nature"},{"key":"443_CR71","first-page":"D498","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498\u2013D503 (2020).","journal-title":"Nucleic Acids Res."},{"key":"443_CR72","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."},{"key":"443_CR73","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinf. 14, 128 (2013).","journal-title":"BMC Bioinf."},{"key":"443_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1603-1","volume":"19","author":"M Stoeckius","year":"2018","unstructured":"Stoeckius, M. et al. Cell hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biol. 19, 224 (2018).","journal-title":"Genome Biol"},{"key":"443_CR75","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293\u20131308 (2018).","journal-title":"Cell"},{"key":"443_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"443_CR77","doi-asserted-by":"publisher","first-page":"861","DOI":"10.21105\/joss.00861","volume":"3","author":"L McInnes","year":"2018","unstructured":"McInnes, L. et al. UMAP: Uniform Manifold Approximation and Projection for dimension reduction. J. Open Source Softw. 3, 861 (2018).","journal-title":"J. Open Source Softw."},{"key":"443_CR78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","volume":"162","author":"JH Levine","year":"2015","unstructured":"Levine, J. H. et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184\u2013197 (2015).","journal-title":"Cell"},{"key":"443_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0844-5","volume":"16","author":"G Finak","year":"2015","unstructured":"Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).","journal-title":"Genome Biol."},{"key":"443_CR80","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong, E. et al. Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity. Immunity 55, 308\u2013323 (2022).","journal-title":"Immunity"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00443-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00443-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00443-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T17:02:58Z","timestamp":1707584578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-022-00443-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":80,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1038\/s43018-022-00443-5","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.W.L. is a consultant and holds equity in Blueprint Medicines, ORIC Pharmaceuticals, Mirimus, PMV Pharmaceuticals, Faeth Therapeutics, Senescea Therapeutics, and Constellation Pharmaceuticals. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}